Home
Clinical Resources Search
PQI: Chemotherapy Induced Peripheral Neuropathy

Chemotherapy Induced Peripheral Neuropathy

Download PQI pdf 0.17MB

Last Updated: September 5, 2023

By: Andrea Clarke, PharmD | Becky Fahrenbruch, PharmD, BCOP

About this PQI

Chemotherapy-induced peripheral neuropathy (CIPN) is a serious side effect that can occur with chemotherapeutics, including certain oral chemotherapy agents. Appropriate patient education and monitoring may assist with identifying early signs of peripheral neuropathy, but no agents have demonstrated efficacy in preventing CIPN. When patients experience chronic peripheral neuropathy not relieved by dose reductions or interruptions, further treatment may be warranted. Currently, the strongest evidence supports the use of duloxetine as treatment for CIPN. Other agents have demonstrated mixed results but may be useful for individual patients.

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care. Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Find a PQI

Find Similar Resources

All Resources

PQI PQI in Action PQI Podcast Toolkit Treatment Support Kit Video Neuropathy Adcetris Brentuximab Vedotin Cabazitaxel Capecitabine Enfortumab Vedotin Iclusig Jevtana Lorbrena Lorlatinib Nexavar Padcev Ponatinib Regorafenib Sorafenib Stivarga Supportive Care Xeloda

PQI

PQI: Ibrutinib Dosing Optimization

Author: Nick Bouchard, PharmD | Danielle Maciorowski, PharmD

Frequently Searched

Supported by

Chemotherapy Induced Peripheral Neuropathy

About this PQI

How to Use a Positive Quality Intervention (PQI)

Find Similar Resources

PQI: Ibrutinib Dosing Optimization

PQI: Zanubrutinib (Brukinsa®) Patient Selection and Management

PQI: Zanubrutinib (Brukinsa ®) treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

PQI: Vorasidenib (Voranigo®)

PQI in Action: Tepotinib (Tepmetko®) for Non-Small Cell Lung Cancerwith MET Exon 14 Alterations

PQI in Action: Siltuximab (Sylvant®) in Patients with Idiopathic Multicentric Castleman Disease

PQI in Action: Isatuximab-irfc (Sarclisa®) in 1q21 Gain or Amplifications in Relapsed/Refractory Multiple Myeloma

PQI in Action: Adagrasib (Krazati®)

The PQI Podcast S3 Ep 11: Moffitt Clinical Pharmacy Program

The PQI Podcast S3 Ep 12: Health Disparities in Cancer Screenings

The PQI Podcast S3 Ep 13: The Importance of the Multidisciplinary Team

The PQI Podcast S3 Ep 14: The Venetoclax PQI and AML Updates

Readiness Tracker

Treatment Support Kit: Abemaciclib

Treatment Support Kit: Temozolomide

Treatment Support Kit: Tivozanib

Treatment Support Kit: Regorafenib

Video: BRUKINSA® (Zanubrutinib) for Treatment of Relapsed or Refractory Marginal Zone Lymphoma

Video: BRUKINSA® (Zanubrutinib) for Treatment of Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Video: BRUKINSA® (Zanubrutinib) for Treatment of Mantle Cell Lymphoma

Video: BRUKINSA® (Zanubrutinib) for Treatment of Waldenstrom’s Macroglobulinemia

PQI: Brentuximab Vedotin (Adcetris®) Neuropathy and Neutropenia Management

PQI: Brentuximab Vedotin (Adcetris®) Neuropathy and Neutropenia Management

PQI: Brentuximab Vedotin (Adcetris®) Neuropathy and Neutropenia Management

PQI: Cabazitaxel (Jevtana®) for Patients with Metastatic Castration-Resistant Prostate Cancer

PQI in Action: Cabazitaxel (Jevtana®) for Patients with Metastatic Castration Resistant Prostate Cancer – 2

PQI in Action: Cabazitaxel (Jevtana®) for Patients with Metastatic Castration Resistant Prostate Cancer – 1

PQI Podcast S5 Ep 13: NCODA Residency & Capecitabine PQI

PQI: DPYD Testing Prior to Fluoropyrimidine Treatment

Treatment Support Kit: Capecitabine

PQI: Capecitabine (Xeloda®): A New Approach to Dosing and Side Effect Management

PQI: Enfortumab Vedotin-ejfv (Padcev®) Management for Advanced or Metastatic Urothelial Carcinoma

PQI: Enfortumab Vedotin-ejfv (Padcev®) and Pembrolizumab (Keytruda®) Management for Advanced or Metastatic Urothelial Carcinoma

PQI in Action: Enfortumab Vedotin (Padcev®) Management for Advanced or Metastatic Urothelial Carcinoma – 2

PQI in Action: Enfortumab Vedotin (Padcev®) Management for Advanced or Metastatic Urothelial Carcinoma

PQI: Ponatinib (Iclusig®) Patient Management

PQI: Cabazitaxel (Jevtana®) for Patients with Metastatic Castration-Resistant Prostate Cancer

PQI in Action: Cabazitaxel (Jevtana®) for Patients with Metastatic Castration Resistant Prostate Cancer – 2

PQI in Action: Cabazitaxel (Jevtana®) for Patients with Metastatic Castration Resistant Prostate Cancer – 1

PQI: Lorlatinib (Lorbrena®) Clinical Management

PQI: Lorlatinib (Lorbrena®) Clinical Management

PQI: Sorafenib (Nexavar®) for the Treatment of Hepatocellular Carcinoma and Transition to Second-line Regorafenib (Stivarga®)

PQI: Enfortumab Vedotin-ejfv (Padcev®) Management for Advanced or Metastatic Urothelial Carcinoma

PQI: Enfortumab Vedotin-ejfv (Padcev®) and Pembrolizumab (Keytruda®) Management for Advanced or Metastatic Urothelial Carcinoma

PQI in Action: Enfortumab Vedotin (Padcev®) Management for Advanced or Metastatic Urothelial Carcinoma – 2

PQI in Action: Enfortumab Vedotin (Padcev®) Management for Advanced or Metastatic Urothelial Carcinoma

PQI: Ponatinib (Iclusig®) Patient Management

PQI: Sorafenib (Nexavar®) for the Treatment of Hepatocellular Carcinoma and Transition to Second-line Regorafenib (Stivarga®)

PQI: Regorafenib (Stivarga®) in the Treatment of Hepatocellular Carcinoma

PQI: Regorafenib (Stivarga®) in Metastatic Colorectal Cancer

Treatment Support Kit: Regorafenib

PQI: Sorafenib (Nexavar®) for the Treatment of Hepatocellular Carcinoma and Transition to Second-line Regorafenib (Stivarga®)

PQI: Sorafenib (Nexavar®) for the Treatment of Hepatocellular Carcinoma and Transition to Second-line Regorafenib (Stivarga®)

PQI: Regorafenib (Stivarga®) in the Treatment of Hepatocellular Carcinoma

PQI: Regorafenib (Stivarga®) in Metastatic Colorectal Cancer

Treatment Support Kit: Regorafenib

The PQI Podcast S4 Ep 5: Role of Oncology Social Worker

The PQI Podcast S4 Ep 6 : Community Pharmacy and Ohio Board of Pharmacy

The PQI Podcast S4 Ep 9: Mental Illness and Burnout

The PQI Podcast S4 Ep 10: Oncology Wellness & Exercise

PQI Podcast S5 Ep 13: NCODA Residency & Capecitabine PQI

PQI: DPYD Testing Prior to Fluoropyrimidine Treatment

Treatment Support Kit: Capecitabine

PQI: Capecitabine (Xeloda®): A New Approach to Dosing and Side Effect Management

The PQI Podcast S3 Ep 11: Moffitt Clinical Pharmacy Program

The PQI Podcast S3 Ep 12: Health Disparities in Cancer Screenings

The PQI Podcast S3 Ep 13: The Importance of the Multidisciplinary Team

The PQI Podcast S3 Ep 14: The Venetoclax PQI and AML Updates